Companies · Pharmaceuticals

Effcon MXR LLC

ATLANTA · Pharmaceuticals

Diligence memoA one-page analyst read on Effcon MXR LLC — recommendation, valuation, rhythm, risks.
$6.5M
Total raised · real
4
Rounds
0.7×
Latest step-up
Top 54%
Sector rank · raised
Seed
Latest stage · inferred · Fri Oct 30 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Effcon MXR LLC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.42× the median modeled value of Seed Pharmaceuticals companies in 2007–2009 (25 peers) — value vs value, same stage and era.
Dormant
  • Last raise 16.7 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Effcon MXR LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
56.5 yr record
Peak capital year was Undated with $8.3M across 3 filings.
Market position
ahead of 47% of Pharmaceuticals peers
Capital scale is ahead of 47% of Pharmaceuticals peers; modeled value is above 35% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in Undated: $8.3M across 3 filings.
  • Largest single filing was $3.0M on .
  • Filing rows sum to $9.5M, while canonical raised total is $6.5M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Effcon MXR LLC is one of 1613 Pharmaceuticals companies tracked from ATLANTA. By capital raised it ranks mid-pack (ahead of 47% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · Raised $3.0M (real) Modeled valuation $5.0M (est)$3.0M$5.0MSeedSeed · Raised $3.0M (real) Modeled valuation $5.0M (est)$3.0M$5.0MSeedSeed · Raised $2.3M (real) Modeled valuation $3.8M (est)$2.3M$3.8MSeedPre-Seed · 2009-10-30 Raised $722K (real) Modeled valuation $34M (est)$722K$34MPre-Seed2009Pre-Seed · 2009-10-30 Raised $522K (real) Modeled valuation $25M (est)$522K$25MPre-Seed2009+$3.0M+$2.3M+$722K+$522KCumulative $9.5M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.0M
Seed extension$3.0M
Seed extension$2.3M
Bridge · Seed-stage$722K · 2009smaller follow-on
Bridge · Seed-stage$522K · 2009smaller follow-on

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$34.1M
Base estimate est.
$404K
Conservative case
$387.0M
Upside case
$4.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $5.0M · Seed · modeled $5.0M · Seed · modeled $3.8M · Pre-Seed · modeled $34.1M · 2009-10-30Pre-Seed · modeled $24.7M · 2009-10-302009
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
6.0 yr
Elapsed time used
16.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
119 mo
Avg between rounds
$164K/yr
Capital velocity
56.5 yr
On record since
1970
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$6.5M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.3× of median
This company$522K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$34.1M
Sector median$76.1M

Raised more than 47% of sector peers (real $). Modeled value above 35% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #24 of 25.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Sequoia Pharmaceuticals Inc · Seed Raised $3.8M · modeled $144.6M (est)Spring Pharmaceuticals, LLC · Seed Raised $6.1M · modeled $142.7M (est)Oceana Therapeutics, Inc. · Seed Raised $3.0M · modeled $114.1M (est)Supergen Inc · Seed Raised $3.0M · modeled $114.1M (est)Archer Pharmaceuticals, Inc. · Seed Raised $2.7M · modeled $102.7M (est)Cequent Pharmaceuticals Inc · Seed Raised $2.7M · modeled $100.9M (est)Anthill Technologies Inc · Seed Raised $2.6M · modeled $97.6M (est)Vpi Holdings Corp · Seed Raised $2.5M · modeled $95.1M (est)Raptor Pharmaceuticals Corp. · Seed Raised $2.4M · modeled $90.8M (est)Groupe Athena, Inc. · Seed Raised $2.4M · modeled $89.6M (est)Mediquest Therapeutics Inc · Seed Raised $2.3M · modeled $87.8M (est)Bridge Pharmaceuticals, Inc. · Seed Raised $2.2M · modeled $83.3M (est)Effcon MXR LLC (this company) Raised $6.5M · modeled $34.1M (est)Effcon MXR LLC
CompanyStageRaised · realValue · estvs peer med.
Sequoia Pharmaceuticals IncSeed$3.8M$144.6M1.79×
Spring Pharmaceuticals, LLCSeed$6.1M$142.7M1.77×
Oceana Therapeutics, Inc.Seed$3.0M$114.1M1.42×
Supergen IncSeed$3.0M$114.1M1.42×
Archer Pharmaceuticals, Inc.Seed$2.7M$102.7M1.27×
Cequent Pharmaceuticals IncSeed$2.7M$100.9M1.25×
Anthill Technologies IncSeed$2.6M$97.6M1.21×
Vpi Holdings CorpSeed$2.5M$95.1M1.18×
Raptor Pharmaceuticals Corp.Seed$2.4M$90.8M1.13×
Groupe Athena, Inc.Seed$2.4M$89.6M1.11×
Mediquest Therapeutics IncSeed$2.3M$87.8M1.09×
Bridge Pharmaceuticals, Inc.Seed$2.2M$83.3M1.03×
Effcon MXR LLC this companySeed$6.5M$34.1M0.42×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$722K2009-10-30$4.0M$34.1M90%
Pre-Seed$522K2009-10-30$2.9M$24.7M90%
Seed$3.0M$15.0M$5.0M90%
Seed$3.0M$15.0M$5.0M90%
Seed$2.3M$11.4M$3.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$722K2009-10-30
    • First recorded raise — entered as Pre-Seed.
  2. Pre-Seed$522K2009-10-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.4× smaller than the prior — bridge or down round.
Intelligence
2019 ~Q4
Modeled next raise · ~119mo cadence
$522K
Modeled next size est.range $522K$835K
0.7×
Last step-up
$164K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ed Burklow2009-10
Hal Folds2009-10
Harris "Bo" Simpson2009-10
Registry & provenance

Effcon MXR LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1474397
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Topical Remedy, LLCPharmaceuticalsSeed$6.3M$22.8Msame sector · same stage
Revere Pharmaceuticals Inc.PharmaceuticalsSeed$6.1M$13.6Msame sector · same stage
iCeutica IncPharmaceuticalsSeed$6.0M$38.4Msame sector · same stage
Microdermis CorpPharmaceuticalsSeed$7.9M$52.8Msame sector · same stage
Achelios Therapeutics, Inc.PharmaceuticalsSeed$5.4M$13.3Msame sector · same stage
Sequel Pharmaceuticals IncPharmaceuticalsSeed$5.4M$38.0Msame sector · same stage
Oligomerix, Inc.PharmaceuticalsSeed$8.3M$37.8Msame sector · same stage
Resilience Therapeutics, Inc.PharmaceuticalsSeed$8.4M$19.0Msame sector · same stage
Frequently asked
How much funding has Effcon MXR LLC raised?
Effcon MXR LLC has raised approximately $6.5M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is Effcon MXR LLC's estimated valuation?
Provath's modeled valuation for Effcon MXR LLC is approximately $34.1M (modeled range $404K–$387.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Effcon MXR LLC at?
Effcon MXR LLC's latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Oct 30.
What does Effcon MXR LLC do and where is it based?
Effcon MXR LLC operates in the Pharmaceuticals sector, based in ATLANTA.
Explore related

See where Effcon MXR LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Effcon MXR LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.